Este sitio web está dirigido a profesionales sanitarios de España

blog-artritis-logo
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • subtitles off, selected

       

      Autor

      Dr. Héctor Corominas
      Director del Servei de Reumatologia i Malalties Sistèmiques. Hospital de la Santa Creu i Sant Pau. Barcelona. Universitat Autònoma de Barcelona (UAB).  

      Actualidad científica en Artritis Reumatoide

      Consulta lo último en Artritis Reumatoide con nuestra selección de artículos, recursos, y otros materiales de interés

      Referencias
      1. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs. 1999;58(6):1137-64.
      2. Smolen JS, Graninger WB, Emery P. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology. 2000;39(7):689-92. 
      3. Dougados M, Emery P, Lemmel EM, Rodríguez de la Serna A, Zerbini CAF, Antoine C, et al. Maintenance rate of leflunomide in patients with rheumatoid arthritis: RELIEF 1-year data. Arthritis Rheum. 2001;44(Supl 1):S173.
      4. Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a cotherapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2009;68(1):33-9. 
      5. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol. 2010;29(5):517-24. 
      6. Strangfeld A, Hierse F, Kekow J, Von Hinueber U, Tony HP, Dockhorn R, et Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68(12):1856-62. 
      7. Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. J Rheumatol. 2016;43(10):1787-94. 
      8. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374-7. 
      9. Nar Narváez J, Díaz-Torné C, Magallares B, Hernández MV, Reina D, Corominas H, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS 2015;10(4):e0123392. 
      10. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99.
      11. Nash P. 2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews. Ann Rheum Dis. 2020;79(6):679-80.
      12. Flint J, Panchal S, Hurrell A, Van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding. Part I: Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693-7.
      13. Grupo de trabajo de la GUIPCAR. Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Madrid: Sociedad Española de Reumatología; 2019.
      14. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-904.
      15. Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, Van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20-33.
      16. Tornero-Molina J, Alperi-López M, Castellví I, De Agustín-de Oro JJ, Escudero A, García-Vicuña R, et al. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatol Clin. 2020:S1699-258X(20)30200-X. [Online antes de impresión].

      MAT-ES-2403358-V.1-Noviembre 2024